PDAC antibody-drug conjugate EBC-129 wins FDA fast track status
U.S. regulators have granted fast track status to the Experimental Drug Development Centre’s (EDDC’s) candidate therapy for pancreatic ductal adenocarcinoma (PDAC), an aggressive form…